Dietrich John Pauls
Known title: President and CEOCIK: 0001760123
Dietrich John Pauls's purchase track record
Dietrich John Pauls has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/23/2023 | DMAC | $50K | -34.1% | -32.9% | +9.3% |
| 11/16/2022 | DMAC | $24K | +24.8% | +44.6% | +5.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DMAC | ▲ Buy | Grant | 60,200 | $0 | 8/10/2026 | View on chart |
| DMAC | ▲ Buy | Open Market | 12,787 | $50K | 6/23/2023 | View on chart |
| DMAC | ▲ Buy | Open Market | 20,000 | $24K | 11/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction
DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction. DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.